Top Markets
Coin of the day
PCL, Inc. PCL, Inc.

PCL, Inc.

241820
株式のランク #31786
PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic... PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic (IVD) solutions, encompassing both diagnostic products and specialized platform services. The company's primary offerings include comprehensive multiplex kits designed to detect antibodies to Human Immunodeficiency Virus (HIV) types 1 and 2, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human T-lymphotropic Virus (HTLV) types 1 and 2. These kits also identify specific antigens such as HIV p24, HCV core, and HBV surface markers in human serum or plasma samples. In addition to these, PCL markets Ai, a rapid diagnostic test kit capable of typing influenza A and B strains; Cancer6, a screening kit for multiple tumor biomarkers; and the sciLINER LATERAL FLOW DISPENSER, an advanced dispensing device for membrane materials featuring active visual drop volume control. Beyond its product portfolio, PCL offers valuable platform services. These include a sol-gel spotting service, which immobilizes client-specified materials using the proprietary SolB reagent, and an SG ID service, providing customers with identified molecules of interest securely immobilized within the SolB reagent. PCL, Inc. is headquartered in Seoul, South Korea.
株価
$0.21291741
最終同期: 2025-04-18
時価総額
$12.07M
変化(1日)
0.00%
変化(1年)
0.00%
KR
取引 PCL, Inc. (241820)

カテゴリー

PCL, Inc.(241820)の収益
Sep 2025 時点の収益 TTM: $3.55M
PCL, Inc. の最新の財務報告によると、現在の収益 (TTM) は $3.55M です。2023 年には $6.51M の収益があり、これは 2022 年の $29.49M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
PCL, Inc. の収益履歴(2015 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $3.55M 318.67%
2024 $847.63K -86.98%
2023 $6.51M -77.92%
2022 $29.49M -24.02%
2021 $38.82M -21.50%
2020 $49.45M 159,346.74%
2019 $31.01K -73.14%
2018 $115.44K -75.69%
2017 $474.92K -2.74%
2016 $488.29K 136.13%
2015 $206.79K 0.00%
同業他社の収益
企業 収益 収益の差
$46.59B 1,312,601.74%
US
$25.84B 727,951.41%
US
$35.48B 999,790.71%
IE
$21.00B 591,538.63%
US
$6.51B 183,407.73%
US